Pharmacokinetics of Oral Treprostinil in Patients With Systemic Sclerosis
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
This study will assess the pharmacokinetic and safety profile of treprostinil following fixed
and escalating doses of treprostinil diethanolamine SR tablets. Open-label, two-part study
assessing the pharmacokinetics, safety, and tolerability of oral treprostinil diethanolamine
SR. Cohort 1: single 1 mg treprostinil diethanolamine SR dose. Cohort 2: escalating doses of
treprostinil diethanolamine SR up to a target dose of 4 mg BID.